DiagnaMed Holdings Corp. provided a development and commercialization update for CERVAI?, a brain health AI platform. A world first, CERVAI?

consists of a Brain Age Estimation and Brain Health Assessment tool. The Brain Age Estimation tool includes a novel electroencephalogram headset and machine-learning model. It integrates proprietary software into unified and standardized data recording protocols.

The Brain Health Assessment tool generates clinician-observed measures and a brain health score. These combined allow users to be proactive in achieving their brain health goals. Future versions of CERVAI?

will incorporate OpenAI's GPT platform to develop personalized treatment plans. The Company is working with Drexel University to complete the Brain Age tool of CERVAI?. The first phase of the Brain Age program, which involved EEG recordings of participants at a research site, is complete.

A novel lightweight, inexpensive, and easy-to-use EEG headset recorded the EEG data. A proprietary machine-learning model processed the EEG data to predict brain ages. The current model predicted chronological ages with a medium-to-strong statistical effect size.

The final phase of the Brain Age program, which involved EEG recordings of participants at home, is complete. Final results from the clinic and home studies will be published this year to support DiagnaMed?s commercialization initiatives. The initial commercial version of CERVAI?

will be ready for launch in Q4-2023. CERVAI? can be available at health centers, doctor offices, hospitals, clinics, pharmacies, and homes.

The Company is finalizing commercial support materials (i.e. training, customer support, marketing). Discussions with clinics and research centers for CERVAI? in Canada and the U.S. are taking place.

DiagnaMed plans to partner with digital health companies for international commercialization.